Diffuse Cutaneous Systemic Sclerosis
Philikos B.V. focuses on clinical research in diffuse cutaneous systemic sclerosis, a severe form of autoimmune connective tissue disease marked by progressive skin thickening and multi-organ involvement.
- Early-stage dcSSc
- Skin fibrosis
- Systemic autoimmune disease
The sponsor’s activity in this area centers on therapeutic options for patients with early disease, with attention to the clinical burden of fibrotic progression and related inflammatory features.
Immune-Mediated Fibrosis
Its research interest extends to immune-driven fibrotic disorders, where abnormal immune activity contributes to tissue remodeling and persistent hardening of the skin.
- Fibroinflammatory processes
- Collagen deposition
- Tissue remodeling
This therapeutic domain reflects a focus on conditions in which controlling fibrosis is central to preserving function and limiting disease impact.
Autoimmune Disease Therapy
Philikos B.V. also operates within the broader field of autoimmune disease therapy, with emphasis on disorders characterized by dysregulated immune responses and chronic inflammation.
- Immune modulation
- Inflammatory skin disease
- Connective tissue involvement
Within this landscape, the sponsor is engaged in research relevant to clinical pathways that address both immune activity and structural tissue change.
